Repurchase Report

Innovation Medical Management Co., Ltd. (hereinafter referred to as "the Company") and all members of the Board of Directors guarantee that the information disclosed is true, accurate, and complete, without false records, misleading statements, or significant omissions.

Special Reminder:

1. The Company has decided to repurchase its shares using its own funds through centralized bidding to maintain company value and protect shareholder interests. The total amount for the repurchase will not be less than RMB 50 million (inclusive) and not exceed RMB 100 million (inclusive), with a repurchase price not exceeding RMB 20 per share. The implementation period for the repurchase will be within three months from the date the Board of Directors approves the repurchase plan.
2. This matter has been approved by the Company's seventh Board of Directors at the third extraordinary meeting in 2026. According to the Company Law, the Company's Articles of Association, and other relevant regulations, this share repurchase does not require submission to the shareholders' meeting for approval.
3. The Company has opened a special securities account for share repurchase at the Shenzhen branch of China Securities Depository and Clearing Co., Ltd.
4. Relevant risk warnings for this repurchase plan include: (1) the risk that the funds required for the repurchase may not be raised, leading to the inability to implement the repurchase plan; (2) the risk that the stock price may continue to exceed the disclosed upper limit of the repurchase price during the repurchase period, leading to the inability to implement the plan or only partial implementation; (3) the risk that significant events affecting the stock price or the Board's decision to terminate the repurchase plan may prevent implementation; (4) the Company will fulfill its information disclosure obligations in a timely manner based on the progress of the repurchase, and investors should pay attention to risks.

According to the Company Law, Securities Law, Shenzhen Stock Exchange Listing Rules, and the Shenzhen Stock Exchange Self-Regulatory Guidelines No. 9 - Share Repurchase, and based on firm confidence in the Company's future development prospects and value judgment, combined with the current financial and operational status, the Company has prepared this "Repurchase Report," with specific details as follows:

1. Main Content of the Repurchase Plan

(1) Purpose of the Share Repurchase

In light of the recent continuous decline in the Company's stock price, which has dropped by a cumulative 20% over twenty consecutive trading days (from April 30, 2026, to June 1, 2026), and the closing price being below 50% of the highest closing price in the past year, the Company has decided to repurchase shares using its own funds through centralized bidding to maintain company value and protect shareholder interests.

(2) Compliance with Relevant Conditions

The share repurchase complies with the following conditions stipulated in Article 10 of the Shenzhen Stock Exchange Self-Regulatory Guidelines No. 9 - Share Repurchase:

1. The Company's stock has been listed for more than six months;
2. The Company has had no major legal violations in the past year;
3. After the repurchase, the Company will have the ability to fulfill its debts and continue operations;
4. The distribution of shares after the repurchase should generally meet listing conditions; if the Company intends to terminate its stock listing through the repurchase, it must comply with relevant regulations and obtain approval from the Shenzhen Stock Exchange;
5. Other conditions stipulated by the China Securities Regulatory Commission and the Shenzhen Stock Exchange.

The Company's stock has dropped by a cumulative 25.92% over twenty consecutive trading days (from April 30, 2026, to June 1, 2026), and the closing price on June 1, 2026, was 53.42% lower than the highest closing price in the past year (RMB 36.99 per share).